Neuropsychiatry – Talk Bio

Actionable Insights Powered by AI

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Neurodevelopmental Disorders, Neuropsychiatry, proposal - intent, Zurzuvae

Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry